BETIMOL

LOE ApproachingSM

timolol

NDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

CLINICAL PHARMACOLOGY Timolol is a non-selective beta-adrenergic antagonist. It blocks both beta 1 -and beta 2 -adrenergic receptors. Timolol does not have significant intrinsic sympathomimetic activity, local anesthetic (membrane-stabilizing) or direct myocardial depressant activity. Timolol, when…

Clinical Trials (5)

NCT07168902Phase 2Recruiting

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

Started Oct 2025
228 enrolled
Glaucoma
NCT04828057N/ACompleted

Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

Started Sep 2021
50 enrolled
Ocular Surface DiseasePrimary Open Angle Glaucoma
NCT04742283Phase 2Completed

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Started Dec 2020
323 enrolled
Primary Open Angle GlaucomaOcular Hypertension
NCT03931317N/ACompleted

Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity

Started Dec 2018
70 enrolled
OAG - Open-Angle GlaucomaOHT - Ocular Hypertension
NCT03691662Phase 3Completed

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Started Sep 2018
417 enrolled
Glaucoma and Ocular Hypertension